Evidence map›Paper›PMID 31806773›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET.

Andrea Farolfi, Harun Ilhan, Andrei Gafita, Jeremie Calais, Francesco Barbato, Manuel Weber, Ali Afshar-Oromieh, Fabian Spohn, Axel Wetter, Christoph Rischpler and 7 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. European journal of nuclear medicine and molecular imaging · 2022
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Andrea FarolfiNuclear Medicine Unit, University of Bologna, S. Orsola Hospital, Bologna, Italy.
Harun IlhanDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany.
Andrei GafitaDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Francesco BarbatoDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Manuel WeberDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Ali Afshar-OromiehDepartment of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Fabian SpohnDepartment of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Axel WetterDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Christoph RischplerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Boris HadaschikDepartment of Urology, University Hospital Essen, Essen, Germany.
Davide PianoriDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; and.
Stefano FantiNuclear Medicine Unit, University of Bologna, S. Orsola Hospital, Bologna, Italy.
Uwe HaberkornDepartment of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Matthias EiberDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Wolfgang Peter FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany wolfgang.fendler@uk-essen.de.
University of Duisburg-Essen · DEDeutschen Konsortium für Translationale Krebsforschung · DEEssen University Hospital · DEHeidelberg University · DEKlinikum rechts der Isar · DEUniversity of Bologna · ITLudwig-Maximilians-Universität München · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET.

Indexed as

Lymph Node ExcisionPositron-Emission TomographySalvage TherapyTreatment FailureAntigens, SurfaceGlutamate Carboxypeptidase IIHumansImage Processing, Computer-AssistedMaleProstatic NeoplasmsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIPETprostate cancerPSA persistencePSMAsalvage lymph node dissection

Identifiers

PMID31806773
PMCPMC7383079
OpenAlexW2993683857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.